CCA cell lines HuCCT1 and HuH28 were purchased from Japan Health Science Research Resources Bank, and CCA cell lines SNU-1196, SNU-1079, SNU-308, SNU-245, SNU-478 and SNU-869 were purchased from Korea Cell Line Bank. Human HEK293T was obtained from American Type Culture Collection (ATCC). All cell lines were cultured with RPMI-1640 medium (Invitrogen, USA) supplemented with 10% fetal bovine serum (Hyclone, USA) and 1% PenStrep (100 U/mL Penicilium and 100 μg/mL Streptomycin) in a humid atmosphere containing 5% CO2 at 37 °C. Gemcitabine resistant cell lines HuCCT1-Gem and SNU-245-Gem were constructed by exposing to increasing dosages of Gemcitabine (Selleck Chemicals, USA) for 8 months, and then persistently cultured in medium containing 10 nmol/l Gemcitabine.
Snu869
Manufactured by Korean Cell Line Bank
Sourced in Japan
The SNU869 is a laboratory equipment product from the Korean Cell Line Bank. It is designed for the cultivation and maintenance of cell lines. The core function of the SNU869 is to provide a controlled and optimal environment for the growth and propagation of various cell types.
Automatically generated - may contain errors
Lab products found in correlation
Snu245, by Korean Cell Line Bank (9 mentions)
Snu478, by Korean Cell Line Bank (9 mentions)
Snu1196, by Korean Cell Line Bank (9 mentions)
Snu1079, by Korean Cell Line Bank (8 mentions)
Snu 308, by Korean Cell Line Bank (7 mentions)
Hucct1, by RIKEN BioResource Center (4 mentions)
Tfk 1, by RIKEN BioResource Center (4 mentions)
Kku m055, by Japanese Collection of Research Bioresources Cell Bank (2 mentions)
Trcn0000196945, by Merck Group (2 mentions)
Kku m213, by Japanese Collection of Research Bioresources Cell Bank (2 mentions)
Mmnk 1, by Japanese Collection of Research Bioresources Cell Bank (2 mentions)
Hucct1, by Japanese Collection of Research Bioresources Cell Bank (2 mentions)
Gemcitabine, by Selleck Chemicals (1 mentions)
Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions)
Hucct1, by Health Science Research Resources Bank (1 mentions)
Huh28, by Health Science Research Resources Bank (1 mentions)
Human hek293t, by American Type Culture Collection (1 mentions)
Azd6738, by AstraZeneca (1 mentions)
Rpmi 1640 medium, by Welgene (1 mentions)
Fetal bovine serum (fbs), by Welgene (1 mentions)
9 protocols using snu869
1
Establishment of Gemcitabine-Resistant CCA Cell Lines
2
BTC Cell Lines and Chemotherapeutics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Nine human BTC cell lines were utilized in this research. The SNU245, SNU308, SNU478, SNU869, SNU1079, and SNU1196 cell lines were purchased from Korean Cell Line Bank (Seoul, Korea). The HuCCT-1 and TFK-1 cell lines were obtained from RIKEN BioResource Center (Ibaraki, Japan). A patient-derived cell line, SNU2670, was successfully established [19 (link)]. All cells were cultured in RPMI-1640 medium (Welgene Inc., Gyeongsan, Korea) containing 10% fetal bovine serum and 10 μg/mL gentamicin at 37°C incubator under 5% CO2. The ATR inhibitor AZD6738 was kindly provided by AstraZeneca (Macclesfield, Cheshire, UK). Gemcitabine, cisplatin, and 5-fluorouracil (5-FU) were purchased from Lilly Korea Co. (Seoul, Korea), JW Pharmaceutical Co. (Seoul, Korea), and Ildong Pharmaceutical Co. (Seoul, Korea), respectively.
3
Establishment and Characterization of BTC Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Nine human BTC cell lines were utilized in this study. SNU245, SNU308, SNU478, SNU869, and SNU1196 cells were purchased from Korean Cell Line Bank (Seoul, Korea). HuCCT-1 and TFK-1 cells were obtained from RIKEN BioResource Center (Ibaraki, Japan). The patient-derived cell lines SNU2670 and SNU2773 were successfully established as described previously [10 (link)]. All cells were cultured in RPMI1640 medium (Welgen Inc., Gyeongsan, Korea) containing 10% fetal bovine serum and 10 μg/mL gentamicin at 37°C under 5% CO2. WEE1 (AZD1775), ATR (AZD6738), and ATM (AZD0156) inhibitors were kindly provided by AstraZeneca (Macclesfield, Cheshire, UK).
4
Establishment of Human BTC Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A total of 11 human BTC cell lines were used in this study. SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079, SNU-1196, and SNU-2823 cell lines were obtained from Korean Cell Line Bank, Seoul, Korea. HuCCT1 and TFK-1 cell lines were obtained from RIKEN BioResource Center, Ibaraki, Japan. HER2-amplified human BTC cell lines, SNU-2670 and SNU-2773, were established from tumor tissues from BTC patients using a previously described method [31 (link)].
All the cell lines were maintained in RPMI-1640 culture media supplemented with 10% fetal bovine serum (WELGENE Inc., Gyeongsan, Korea) and 10 μg/mL gentamicin in a humidified atmosphere containing 5% CO2 at 37°C.
All the cell lines were maintained in RPMI-1640 culture media supplemented with 10% fetal bovine serum (WELGENE Inc., Gyeongsan, Korea) and 10 μg/mL gentamicin in a humidified atmosphere containing 5% CO2 at 37°C.
5
Culturing Cholangiocarcinoma Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The HuCCT1 cell line was purchased from the Health Science Research Resources Bank (Osaka, Japan), whereas other cholangiocarcinoma cell lines (SNU245, SNU308, SNU478, SNU869, SNU1079, and SNU1196) were purchased from the Korean Cell Line Bank (Seoul, Korea). The cell lines were grown in RPMI1640 supplemented with 10% fetal bovine serum (FBS), 25mM HEPES, and 100 μg/ml of penicillin/streptomycin in a 5% CO2 atmosphere at 37°C.
6
Modulation of AXL and GAS6 in Cholangiocarcinoma Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
KKU-M055, KKU-M213, MMNK1 and HUCCT1 cells were purchased from the Japanese Collection of Research Bioresources Cell Bank (JCRB, Osaka, Japan); and SNU245, SNU478, SNU869, SNU1079 and SNU1196 cells were purchased from the Korean Cell Line Bank (KCLB; Seoul, Republic of Korea). All cell lines were maintained in their specified medium supplemented with 10% FBS (SERANA) at 37 °C in a 95% air and 5% CO2 incubator. AXL shRNA in lentiviral was purchased and transfected into HEK293T cells (Sigma Aldrich #TRCN0000196945, 5′-GATTGCCATTGAGAGTCTAGC-3′). Cell media were collected 48 h after and filtered using a 0.45 µm syringe filter to collect viral particles. SNU1196 and HUCCT1 cells (2 × 105 cells/well) were plated into a 96-well plate 24 h before incubation with media containing viral particles overnight at 37 °C. The media were removed and replaced with fresh culture media, and puromycin (2 mg/mL) was used to select stable AXL knockdown cells, which was confirmed by Western blotting. For GAS6 stimulation, cells were kept in serum-free medium for 24 h and then treated with 10 μg/mL or 100 μg/mL AVB-500 with the addition of 50 ng/mL GAS6 (R&D systems #885-GSB-050) for 24 h.
7
Establishment of AXL Knockdown Cell Lines
8
Establishment of Gemcitabine-Resistant BTC Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The human BTC cell lines SNU245, SNU308, SNU478, SNU869, SNU1079, and SNU1196 were purchased from the Korea Cell Line Bank (KCLB, Seoul, Korea). These cell lines were maintained in RPMI1640 (Invitrogen Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, US). NIH-3T3 mouse fibroblast cells were purchased from the American Type Culture Collection (ATCC Manassas, VA, USA) and maintained in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS. We previously established gemcitabine-resistant BTC cells by escalating doses of gemcitabine treatment in SNU-1196 cells, as described in a previous study [19 (link)]. Cells were maintained at 37 °C in a humidified incubator with 5% CO2.
9
BTC Cell Lines and Inhibitor Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Ten human BTC cell lines were used in this study. SNU245, SNU308, SNU478, SNU869, SNU1079, and SNU1196 cells were purchased from the Korean Cell Line Bank (Seoul, Korea). HuCCT-1 and TFK-1 cells were obtained from the RIKEN BioResource Center (Ibaraki, Japan). SNU2670 and SNU2773 cell lines were established from patient-derived cancer cells, as previously described [21 (link)]. All cell lines were cultured in RPMI-1640 medium (Welgen Inc., Gyeongsan, Korea) containing 10% fetal bovine serum and 10 μg/mL gentamicin and were maintained at 37°C in a 5% CO2 atmosphere. WEE1 inhibitor (AZD1775) and PARP inhibitor (olaparib) were provided by AstraZeneca (Macclesfield, Cheshire, UK).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!